Episodios

  • Sailesh Kotecha on Prematurity-associated lung disease
    Nov 27 2025

    Prof Sailesh Kotecha joins Diana Stanley to discuss the series on reframing prematurity-associated lung disease as a continuum that begins before birth and evolves throughout life.

    Cick here to read the full series:

    Looking beyond bronchopulmonary dysplasia: prematurity-associated lung disease and its phenotypes
    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00372-8/fulltext

    Trajectories of prematurity-associated lung disease: lifelong lung health
    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00371-6/fulltext

    Management of prematurity-associated lung disease from infancy through to adulthood
    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00369-8/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    11 m
  • Neil Greening and Hnin Aung on Multidimensional prognostic risk stratification of COPD exacerbations
    Nov 25 2025

    Dr Neil Greening and Dr Hnin Aung join Diana Stanley to discuss a new multidimensional prognostic risk stratification model for COPD exacerbations.


    click here to read the full article:
    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00362-5/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    15 m
  • Finn McQuaid and Matthew Saunders on Tuberculosis and Climate change
    Oct 30 2025

    Dr Finn McQuaid and Dr Matthew Saunders join Arianna Colosio to discuss an analytical framework to describe potential causal relationships between climate change and tuberculosis.

    Click here to read the full article

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    11 m
  • Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis
    Sep 28 2025

    Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.

    Read the full article:

    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanres

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    9 m
  • Guy Brusselle and Celeste Porsbjerg on State-of-the-art insights into prevention, development, and management of asthma
    Sep 28 2025

    Professors Guy Brusselle and Celeste Porsbjerg join us to discuss their recent Series papers on asthma, which will be featured in a cross journal project with The Lancet, published to coincide with a Lancet journal session on asthma at ERS in Amsterdam.

    The Series aims to provide an overview of recent research advances related to asthma; to provide new insights into the genetics, prevention and risk factors for asthma; review advances arising as a result of the use of monoclonal antibody therapeutics; and assess remission in adult patients. Late breaking research will also be included within the journal session and linked to the Series.

    Read the full Series:

    https://www.thelancet.com/series-do/asthma-2025?dgcid=buzzsprout_icw_podcast_asthma25_lanres

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    23 m
  • Joan Soriano on Global Epidemiology of Respiratory Disease
    Jul 17 2025

    Diana Stanley, Deputy Editor at The Lancet Respiratory Medicine, is joined by Dr Joan Soriano to discuss a new series on the global epidemiology of respiratory disease, exploring the diagnostic challenges, global trends, and future directions for prevention.

    Read the full Series:

    https://www.thelancet.com/series-do/global-epidemiology-chronic-respiratory-disease?dgcid=buzzsprout_icw_podcast_lanrescrd25_lanres

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    11 m
  • Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial
    Jul 16 2025

    Carole Mitnick & Lorenzo Guglielmetti join Ari Colosio, deputy editor of The Lancet Respiratory Medicine, to discuss the ENDTB-Q trial to evaluate the efficacy and safety of a drug regiment to treat TB in individuals with pre-extensively drug-resistant tuberculosis.

    Read the full article:

    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00194-8/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanres

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    19 m
  • Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian)
    Jul 16 2025

    This episode is in Italian. For the English version, please see the main feed.

    Lorenzo Guglielmetti sul trial clinico ENDTB-Q per valutare l’efficacia e la sicurezza di un regime di farmaci per curare la tubercolosi in individui con tubercolosi pre-estesa farmaco-resistente.

    Leggi l'articolo completo:

    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00194-8/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanres

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    15 m